Inter Pharma Public Company Limited
Inter Pharma Public Company Limited manufactures, imports, and distributes drug and dietary supplement products for humans and animals in Thailand. It operates through three segments: Human healthcare, Animal healthcare, and Hospital and clinics. The company offers healthcare, anti-aging, and human beauty products, such as medical supplies, nutrition therapy, cosmetics, supplementary food, probio… Read more
Inter Pharma Public Company Limited (IP) - Net Assets
Latest net assets as of September 2025: ฿2.26 Billion THB
Based on the latest financial reports, Inter Pharma Public Company Limited (IP) has net assets worth ฿2.26 Billion THB as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (฿3.20 Billion) and total liabilities (฿936.19 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ฿2.26 Billion |
| % of Total Assets | 70.75% |
| Annual Growth Rate | 66.22% |
| 5-Year Change | 341.72% |
| 10-Year Change | N/A |
| Growth Volatility | 107.74 |
Inter Pharma Public Company Limited - Net Assets Trend (2016–2024)
This chart illustrates how Inter Pharma Public Company Limited's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Inter Pharma Public Company Limited (2016–2024)
The table below shows the annual net assets of Inter Pharma Public Company Limited from 2016 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | ฿2.15 Billion | +1.72% |
| 2023-12-31 | ฿2.12 Billion | +2.13% |
| 2022-12-31 | ฿2.07 Billion | +164.65% |
| 2021-12-31 | ฿783.50 Million | +60.66% |
| 2020-12-31 | ฿487.68 Million | +4.71% |
| 2019-12-31 | ฿465.74 Million | +335.32% |
| 2018-12-31 | ฿106.99 Million | +35.87% |
| 2017-12-31 | ฿78.74 Million | +112.99% |
| 2016-12-31 | ฿36.97 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Inter Pharma Public Company Limited's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 237.8% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | ฿108.00 Million | 5.58% |
| Other Components | ฿1.83 Billion | 94.42% |
| Total Equity | ฿1.94 Billion | 100.00% |
Inter Pharma Public Company Limited Competitors by Market Cap
The table below lists competitors of Inter Pharma Public Company Limited ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
BATI EGE GMYO
IS:BEGYO
|
$34.72 Million |
|
EXACOMPTA CLAIREF. NOM.
F:8KG
|
$34.72 Million |
|
MLG OZ Ltd
AU:MLG
|
$34.74 Million |
|
eXoZymes, Inc.
NASDAQ:EXOZ
|
$34.74 Million |
|
Airtasker Ltd
AU:ART
|
$34.70 Million |
|
PharmGen Science Inc
KO:004720
|
$34.69 Million |
|
Sunny Elec
KO:004770
|
$34.68 Million |
|
LEBON NOM. O.N.
F:88J
|
$34.67 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Inter Pharma Public Company Limited's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 1,913,187,668 to 1,936,761,085, a change of 23,573,417 (1.2%).
- Net income of 37,278,096 contributed positively to equity growth.
- Dividend payments of 12,965,129 reduced retained earnings.
- Other comprehensive income decreased equity by 3,703,228.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ฿37.28 Million | +1.92% |
| Dividends Paid | ฿12.97 Million | -0.67% |
| Other Comprehensive Income | ฿-3.70 Million | -0.19% |
| Other Changes | ฿2.96 Million | +0.15% |
| Total Change | ฿- | 1.23% |
Book Value vs Market Value Analysis
This analysis compares Inter Pharma Public Company Limited's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.29x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 2.55x to 1.29x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-12-31 | ฿1.63 | ฿4.14 | x |
| 2017-12-31 | ฿0.25 | ฿4.14 | x |
| 2018-12-31 | ฿0.42 | ฿4.14 | x |
| 2019-12-31 | ฿1.57 | ฿4.14 | x |
| 2020-12-31 | ฿1.16 | ฿4.14 | x |
| 2021-12-31 | ฿2.60 | ฿4.14 | x |
| 2022-12-31 | ฿5.88 | ฿4.14 | x |
| 2023-12-31 | ฿5.14 | ฿4.14 | x |
| 2024-12-31 | ฿3.20 | ฿4.14 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Inter Pharma Public Company Limited utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 1.92%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 1.96%
- • Asset Turnover: 0.63x
- • Equity Multiplier: 1.56x
- Recent ROE (1.92%) is below the historical average (15.39%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2016 | 42.28% | 12.46% | 1.57x | 2.16x | ฿11.93 Million |
| 2017 | 21.45% | 6.36% | 2.36x | 1.43x | ฿8.39 Million |
| 2018 | 29.52% | 9.46% | 1.63x | 1.91x | ฿19.63 Million |
| 2019 | 9.54% | 11.71% | 0.71x | 1.15x | ฿-2.10 Million |
| 2020 | 11.15% | 11.88% | 0.59x | 1.59x | ฿5.43 Million |
| 2021 | 13.81% | 11.58% | 0.68x | 1.74x | ฿29.05 Million |
| 2022 | 6.17% | 7.80% | 0.50x | 1.57x | ฿-73.77 Million |
| 2023 | 2.65% | 2.85% | 0.60x | 1.54x | ฿-140.53 Million |
| 2024 | 1.92% | 1.96% | 0.63x | 1.56x | ฿-156.40 Million |
Industry Comparison
This section compares Inter Pharma Public Company Limited's net assets metrics with peer companies in the Biotechnology industry.
No peer company data available for comparison.